Bone Metastasis – Pipeline Review, H1 2017, provides an overview of the Bone Metastasis (Oncology) pipeline landscape.
Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. The predisposing factors include certain kinds of cancer (breast, prostate, lung, thyroid, and kidney cancers). Treatment options for bone metastasis are chemotherapy, surgery and radiation therapy.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/289245 .
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Bone Metastasis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bone Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bone Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 17 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.
Bone Metastasis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Browse the full report @ http://www.orbisresearch.com/reports/index/bone-metastasis-pipeline-review-h1-2017 .
– The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Metastasis (Oncology).
– The pipeline guide reviews pipeline therapeutics for Bone Metastasis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Bone Metastasis (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Bone Metastasis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Bone Metastasis (Oncology)
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/289245 .
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Bone Metastasis (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Bone Metastasis (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Amura Holdings Ltd
Deciphera Pharmaceuticals LLC
Eli Lilly and Company
Leadiant Biosciences Inc
Mirati Therapeutics Inc
OPKO Health Inc
Osteologix Holdings Plc
Redx Pharma Plc
Taiho Pharmaceutical Co Ltd
Terpenoid Therapeutics Inc
For any enquires before buying, connect with us @ firstname.lastname@example.org
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
For more information contact email@example.com